Clinical Trials Logo

NK/T Cell Lymphoma Nos clinical trials

View clinical trials related to NK/T Cell Lymphoma Nos.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04484506 Recruiting - Clinical trials for NK/T Cell Lymphoma Nos

Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma

Start date: October 20, 2011
Phase: Phase 2
Study type: Interventional

The optimal first-line treatment for extra-nodal NK/T-cell lymphoma (ENKTL) has not been well-defined. This phase II study aimed to evaluate the efficacy and safety of pegaspargase, cyclophosphamide, vincristine, etoposide and prednisone (COEPL) regimen combined with radiotherapy for patients with newly diagnosed ENKTL.

NCT ID: NCT04365036 Recruiting - Clinical trials for NK/T Cell Lymphoma Nos

A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

Start date: May 2020
Phase: Phase 3
Study type: Interventional

The purpose of this randomized, multi-center,phase Ⅲ clinical trail is to compare the safety and efficacy of sequencial chemoradiotherapy with or without toripalimab (PD-1 antibody) for newly diagnosed early-stage extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)

NCT ID: NCT04231370 Recruiting - Clinical trials for NK/T Cell Lymphoma Nos

Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma

Start date: April 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination with lenalidomide in the treatment of Relapsed/Refractory NK/T-cell lymphoma patients who failed pegaspargase-based regimens.

NCT ID: NCT04127227 Recruiting - Clinical trials for NK/T Cell Lymphoma Nos

Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type

Start date: October 9, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this multi-center,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of Sintilimab with P-GemOx (pegaspargase, gemcitabine and oxaliplatin) regimen for newly diagnosed advanced extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)